| GAL |
Galapagos december 2021
Kempen 6 december 2021Optionality too large to ignoreGoing into the new year, Galapagos stock is in a holding patternawaiting a catalyst to unlock the negative EV value. Given ...
|
avantiavanti |
| GAL |
Analyst reports 2021
Kempen 6 december 2021[b]Optionality too large to ignore[/bGoing into the new year, Galapagos stock is in a holding patternawaiting a catalyst to unlock the negative EV value. Given l...
|
avantiavanti |
| GAL |
Analyst reports 2021
KBC 6 augustus 2021No surprises in Galapagos’ 1H21 financial update, apart from TYK2 compound GLPG3667 now also being envisioned for development in UC in the course of 2022. Given long timelines f...
|
avantiavanti |
| GAL |
Analyst reports 2021
UBS 5 augustus 20212Q21 Results: Cash burn guidance unchanged, clinical progress is what mattersNeutralPT €77.00...
|
avantiavanti |
| GAL |
Analyst reports 2021
Goldman Sachs augustus 2021Galapagos NV (GLPG.AS): 2Q21 First Take: OpEx higher, and Toledoand Tyk2 inhibitor plans expand; our initial thoughts and questionsSellPT €49,00...
|
avantiavanti |
| GAL |
Analyst reports 2021
Kempen 6 augustus 2021No surprises with H121 update, cash burn guidance reiteratedNeutralPT €70.00...
|
avantiavanti |
| GAL |
Analyst reports 2021
Barclays 5 augustus 20212Q21 first take: Focus still on business development Stock Rating/Industry View: Overweight/Positive Price Target: EUR 75.00 ...
|
avantiavanti |
| GAL |
Analyst reports 2021
J.P. Morgan Cazenove 6 augustus 20212Q21 Results: Pipeline timelines reiterated, guidance confirmed. Next key event is filgo EU approval in UC by YE21 ...
|
avantiavanti |
| GAL |
Galapagos juli 2021
Op de analyst draad staan nog een paar andere updates.Morgan StanleyToledo Demonstrates POC, But Next Compound Needed For Higher Doses; TYK2 AdvancingStock Rating OverweightPric...
|
avantiavanti |
| GAL |
Analyst reports 2021
Pipeline Stays Alive, But More Work To DoFirst Glance | CommentJuly 14, 2021RBC Capital Markets, LLCBrian Abrahams (Analyst) (212) 858-7066Stephen Mallon (Senior Associate)Sector: ...
|
avantiavanti |
| GAL |
Analyst reports 2021
Raymond JamesQuick Take From TOLEDO and TYK2 Data DumpOn Wednesday post market-close, the Galapagos team dumped top-line results for theawaited studies for its TOLEDO program and TYK2 progra...
|
avantiavanti |
| GAL |
Analyst reports 2021
Morgan StanleyToledo Demonstrates POC, But Next Compound Needed For Higher Doses; TYK2 AdvancingStock Rating OverweightPrice Target $118.00Matthew Harrison, Connor MeehanJuly 15, 2...
|
avantiavanti |
| GAL |
Galapagos juni 2021
Ik heb destijds een bericht gestuurd naar Galapagos over waar de 150 miljoen opt in precies betrekking op had. Kan het antwoord niet meer terugvinden, maar herinner mij dat de bewoording per compound ...
|
avantiavanti |
| GAL |
Galapagos April 2021
Morgan Stanley samenvatting. Hoop later op de dag full report te plaatsen op analyst draad. Bristols TYK2 Safety Is a Positive for GLPG3667Stock Rating OverweightPrice Target $...
|
avantiavanti |
| GAL |
Analyst reports 2021
Recommended Price Target 78,13Buy 5Sell 2Hold 14No Rating 0BAMLJason Gerberry€78.60HoldBarclaysRosie Turner€80BuyBernsteinWimal Kapadia€67HoldBryan, Garnier...
|
avantiavanti |
| GAL |
Analyst reports 2021
Deutsche Bank 20 april 2021PT 110 EURBiotechnology Galapagos Initiation of CoverageWorthwhile journeys of discovery carry risk: initiate with BuyAfter the pipeline setbacks of...
|
avantiavanti |
| GAL |
Inhoudelijk Toledo Draadje
Rigorous new review of SIKs biology and therapeutic potential for diseaseses.Nuts and bolts of the salt-inducible kinases (SIKs)...
|
avantiavanti |
| GAL |
Analyst reports 2021
Barclays 14 april 2021Stock Rating OVERWEIGHTfrom Equal WeightPrice Target EUR 80.00raised 16% from EUR 69.00Re-evaluating the pipeline: u/g to OW...
|
avantiavanti |
| GAL |
Analyst reports 2021
Morgan Stanley 11 maart 2021Stock Rating OverweightPrice Target $117.00Matthew Harrison, Connor MeehanCatalysts Upcoming; Revising Model for Toledo and TYK2We include both...
|
avantiavanti |
| GAL |
Analyst reports 2021
Goldman Sachs 11 februari 2021Galapagos NV (GLPG.AS): P3 ISABELA 1/2 trials halted due to safety;lowering PT to €64/$77 as we remove ziritaxestat from our model ...
|
avantiavanti |
| GAL |
Analyst reports 2021
Overzicht TPs per 11 februari 2021...
|
avantiavanti |
| GAL |
Analyst reports 2021
Maxim Group 10 februari 2021Ziritaxestat IPF Program Discontinued – DowngradingShares to Hold...
|
avantiavanti |
| GAL |
Analyst reports 2021
Kempen 11 februari 2021Ziritaxestat phase III stopped before futility analysis...
|
avantiavanti |
| GAL |
Analyst reports 2021
Cowen 11 februari 2021GILD AND GLPG DISCONTINUE ZIRITAXESTATSISABELA PH. IIIS IN IPF...
|
avantiavanti |
| GAL |
Analyst reports 2021
Barclays 19 januariStock Rating EQUAL WEIGHTUnchangedPrice Target EUR 85.50lowered -32% from EUR 125.00Recalibrating to the new reality...
|
avantiavanti |
| GAL |
Analyst reports 2021
quote:avantiavanti schreef op 19 januari 2021 10:19:Morgan Stanley extract uit update dd 19 januari 2021En hier full report van Morgan Stanley dd 19 januari 21 waarvan gis...
|
avantiavanti |
| GAL |
Analyst reports 2021
Morgan Stanley extract uit update dd 19 januari 2020Galapagos NV (GLPG.O)Too Many Catalysts In 2021 To Ignore; Upgrade To OverweightGalapagos NV (GLPG.O)RatingFrom: Equal-we...
|
avantiavanti |
| GAL |
inhoudelijk LIGHT
[quote alias=BigMoepf id=13006284 date=202012171651][...Achteraf gezien hadden ze misschien beter alleen de 200mg aangevraagd. Dan had de FDA alvast geen mening over de dosages moeten geven.[/qu...
|
avantiavanti |
| GAL |
Analyst reports 2020
Degroof Petercam 16 december (na webast)HoldPT €90Downside risk materially reduced, but patience prevails...
|
avantiavanti |
| GAL |
Analyst reports 2020
Stifel na de webcast Sticking To The Sidelines Given Need For Higher Spend In An Intensely Competitive Landscape; Target Price Moves To $105...
|
avantiavanti |
| GAL |
Analyst reports 2020
JP Morgan CazenoveNeutralPT naar 100 euro van 120...
|
avantiavanti |
| GAL |
Analyst reports 2020
CitiBuy/High Risk 1HPrice (15 Dec 20 16:30) €97.06Target price €148.00...
|
avantiavanti |
| GAL |
Analyst reports 2020
BarclaysStock Rating/Industry View: Equal Weight/PositivePrice Target: EUR 125.00...
|
avantiavanti |
| GAL |
Analyst reports 2020
Stifel HoldPT $135...
|
avantiavanti |
| GAL |
Analyst reports 2020
Kempen vanochtend Buy PT 160 euro...
|
avantiavanti |
| GAL |
Analyst reports 2020
RBC extract updateGILD/GLPG: Gone But Not Filg-otten, As FDA Intransigence Forces Partnership RethinkDecember 15, 2020RBC Capital Markets, LLCBrian Abrahams (Analyst...
|
avantiavanti |
| GAL |
Analyst reports 2020
Morgan Stanley extract updateGilead/Galapagos: Gilead Returns Filgotinib in Europe, Will Not Proceed With non-IBD Indications in USMatthew Harrison, Connor Meehan, Thomas F Lavery, J.D....
|
avantiavanti |
| GAL |
Analyst reports 2020
Raymond James 15 december 2020Type A Let Them Know: US FDA Did the Heisman on Filgo...
|
avantiavanti |
| GAL |
Analyst reports 2020
Jefferies 16 december 2020Galapagos (GLPG NA | GLPG)HOLD, €98.12 | $117.53 PT: €118.00 | $139.50Partner Gilead is discontinuing pursuit of US filgotinib approval for arthritis after meeting FD...
|
avantiavanti |
| GAL |
Inhoudelijk Toledo Draadje
Credit Suisse 10 december 2020GLPG / GILD: SIK Inhibitor Mini Primer: Understanding the Mechanism Behind the Toledo Program Stock Implications[i]Note: ik heb de inhoud van dit rap...
|
avantiavanti |
| GAL |
Analyst reports 2020
Credit Suisse 10 december 2020GLPG / GILD: SIK Inhibitor Mini Primer: Understanding the Mechanism Behind the Toledo Program Stock Implications[i]Note: ik heb de inhoud van dit rap...
|
avantiavanti |
| GAL |
Analyst reports 2020
Maxim Group 1 december 2020BuyPT $170Building-Out The IPF Franchise; Positive Phase 2 Data Reported for GLPG1205...
|
avantiavanti |
| GAL |
Analyst reports 2020
Extract update Credit Suisse 30 november 2020Galapagos NV - Positive Topline Results from Phase 2 PINTA Trial; IPF Assets Continue to Support Evolving GLPG storyAs anticipated, Galapago...
|
avantiavanti |
| GAL |
Analyst reports 2020
Extract RBC Capital Markets 30 november 20GLPG US - Another IPF Drug Shows Promising Signals, Though Remains EarlyRBC Capital Markets, LLCBrian Abrahams (Analyst) (212) 858-7066
...
|
avantiavanti |
| GAL |
Analyst reports 2020
Extract Bofa Securities 30 november 20PINTA (IPF): small victory with +ve Ph2a but clinical utility remains a question markMaintain Rating: UNDERPERFORMPO: 121.00 USD | Pr...
|
avantiavanti |
| GAL |
Analyst reports 2020
Extract update Morgan Stanley 30 november 2020Stock Rating Equal-weightPrice Target $159.00Matthew Harrison, Connor MeehanGLPG1205 leads to ~55% reduction in FVC decline: Mgt....
|
avantiavanti |
| GAL |
Analyst reports 2020
[i]Note: lijvig rapport dus heb ik pdf compressed, zodat het hier past. Daarmee wat rafelig her en der. Maxim Group is recent gestart Galapagos te volgen. Het rapport bevat ook veel basis info en is...
|
avantiavanti |
| GAL |
Analyst reports 2020
KBC Securities 10 november 2020Galapagos - First patient treated with GLPG3667Galapagos announces first dosing of a psoriasis patient in a phase Ib trial with GLPG3667. The company envi...
|
avantiavanti |
| GAL |
Analyst reports 2020
Stifel 27 oktober 2020[i]Our target price for GLPG shares is $138. This is based on a probability-weighted, risk-adjusted NPV analysis. We assign $34, $2, $1, $5for filgotinib, GLPG1690, Other r...
|
avantiavanti |
| GAL |
Analyst reports 2020
UBS 27 oktober 202012-month rating Neutral12m price target €125.00Healing the SIK? Toledo target reveal does not change the investment case...
|
avantiavanti |